Doxa AB
STO:DOXA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Doxa AB
Net Income (Common)
Doxa AB
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
Doxa AB
STO:DOXA
|
Net Income (Common)
-kr335.4m
|
CAGR 3-Years
-103%
|
CAGR 5-Years
-90%
|
CAGR 10-Years
-36%
|
|
|
O
|
OssDsign AB
STO:OSSD
|
Net Income (Common)
-kr51m
|
CAGR 3-Years
20%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Xvivo Perfusion AB
STO:XVIVO
|
Net Income (Common)
kr25.2m
|
CAGR 3-Years
11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
17%
|
|
|
Bactiguard Holding AB
STO:BACTI B
|
Net Income (Common)
-kr7.8m
|
CAGR 3-Years
47%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
V
|
Vimian Group AB
STO:VIMIAN
|
Net Income (Common)
€31.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
S
|
S2Medical AB (publ)
STO:S2M
|
Net Income (Common)
-kr10.1m
|
CAGR 3-Years
30%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
Doxa AB
Glance View
Doxa AB engages in the development, manufacture, and commercialization of bioceramic dental products. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2014-04-07. The firm develops, manufactures and commercializes products based upon its technology platform of calcium aluminate hydrate and bioactive ceramics. Activities are divided into the therapy areas of orthopedics and odontology. Research areas within orthopedics are methods for treating fractures resulting from osteoporosis, reconstructive orthopedics and coating of implants. Research areas within odontology are tooth restoration and implant fixation.
See Also
What is Doxa AB's Net Income (Common)?
Net Income (Common)
-335.4m
SEK
Based on the financial report for Dec 31, 2025, Doxa AB's Net Income (Common) amounts to -335.4m SEK.
What is Doxa AB's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-36%
Over the last year, the Net Income (Common) growth was 81%. The average annual Net Income (Common) growth rates for Doxa AB have been -103% over the past three years , -90% over the past five years , and -36% over the past ten years .
